Johnson & Johnson (JNJ) 10-Q 30 Apr 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Apr. 04, 2021	Apr. 23, 2021
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 4, 2021
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,633,396,003
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-02
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ22
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Apr. 04, 2021	Jan. 03, 2021
Current assets:
Cash and cash equivalents	$ 12,671	$ 13,985
Marketable securities	11,948	11,200
Accounts receivable, trade, less allowances for doubtful accounts and credit losses $270 (2020, $293)	14,938	13,576
Inventories (Note 2)	9,952	9,344
Prepaid expenses and other	3,024	3,132
Total current assets	52,533	51,237
Property, plant and equipment at cost	46,430	46,804
Less: accumulated depreciation	(28,063)	(28,038)
Property, plant and equipment, net	18,367	18,766
Intangible assets, net (Note 3)	51,110	53,402
Goodwill (Note 3)	35,688	36,393
Deferred taxes on income (Note 5)	8,321	8,534
Other assets	6,538	6,562
Total assets	172,557	174,894
Current liabilities:
Loans and notes payable	3,350	2,631
Accounts payable	8,503	9,505
Accrued liabilities	13,223	13,968
Accrued rebates, returns and promotions	11,919	11,513
Accrued compensation and employee related obligations	2,060	3,484
Accrued taxes on income (Note 5)	1,877	1,392
Total current liabilities	40,932	42,493
Long-term debt (Note 4)	30,263	32,635
Deferred taxes on income (Note 5)	6,507	7,214
Employee related obligations (Note 6)	10,512	10,771
Long-term taxes payable (Note 5)	6,568	6,559
Other liabilities	11,941	11,944
Total liabilities	106,723	111,616
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(15,328)	(15,242)
Retained earnings	116,508	113,890
Less: common stock held in treasury, at cost (487,141,000 and 487,331,000 shares)	38,466	38,490
Total shareholders’ equity	65,834	63,278
Total liabilities and shareholders' equity	$ 172,557	$ 174,894

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Apr. 04, 2021	Jan. 03, 2021
Current assets:
Allowances for doubtful accounts	$ 270	$ 293
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	487,141,000	487,331,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Income Statement [Abstract]
Sales to customers	$ 22,321	$ 20,691
Sales to customers percent to sales	100.00%	100.00%
Cost of products sold	$ 7,063	$ 7,062
Cost of products sold percent to sales	31.70%	34.10%
Gross profit	$ 15,258	$ 13,629
Gross Profit Percent To Sales	68.30%	65.90%
Selling, marketing and administrative expenses	$ 5,432	$ 5,203
Selling marketing and administrative expenses percent to sales	24.30%	25.10%
Research and development expense	$ 3,178	$ 2,580
Research and development expense percent to sales	14.20%	12.50%
Interest income	$ (15)	$ (67)
Interest income percent to sales	(0.10%)	(0.30%)
Interest expense, net of portion capitalized	$ 63	$ 25
Interest expense, net of portion capitalized percent to sales	0.30%	0.10%
Other (income) expense, net	$ (882)	$ (679)
Other (income) expense, net percent to sales	(3.90%)	(3.30%)
Restructuring (Note 12)	$ 53	$ 58
Restructuring charge percent to sales	0.20%	0.30%
Earnings before provision for taxes on income	$ 7,429	$ 6,509
Earnings before provision for taxes on income percent to sales	33.30%	31.50%
Provision for taxes on income	$ 1,232	$ 713
Provision for taxes on income (Note 5)	5.50%	3.50%
Net earnings	$ 6,197	$ 5,796
Net earnings percent to sales	27.80%	28.00%
NET EARNINGS PER SHARE
Basic (per share)	$ 2.35	$ 2.20
Diluted net earnings per share	$ 2.32	$ 2.17
AVG. SHARES OUTSTANDING
Basic (shares)	2,631.6	2,633.7
Diluted (shares)	2,672.7	2,671

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Statement of Comprehensive Income [Abstract]
Net earnings	$ 6,197	$ 5,796
Other comprehensive income (loss), net of tax
Foreign currency translation	276	(1,519)
Securities:
Unrealized holding gain (loss) arising during period	0	2
Reclassifications to earnings	0	0
Net change	0	2
Employee benefit plans:
Prior service cost amortization during period	(41)	(6)
Gain (loss) amortization during period	274	201
Net change	233	195
Derivatives & hedges:
Unrealized gain (loss) arising during period	(522)	832
Reclassifications to earnings	(73)	138
Net change	(595)	970
Other comprehensive income (loss)	(86)	(352)
Comprehensive income	$ 6,111	$ 5,444

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 29, 2019	$ 59,471	$ 110,659	$ (15,891)	$ 3,120	$ (38,417)
Net earnings	5,796	5,796
Cash dividends paid	(2,505)	(2,505)
Employee compensation and stock option plans	595	(1,049)			1,644
Repurchase of common stock	(1,711)				(1,711)
Other comprehensive income (loss), net of tax	(352)		(352)
Ending Balance at Mar. 29, 2020	61,294	112,901	(16,243)	3,120	(38,484)
Beginning Balance at Jan. 03, 2021	63,278	113,890	(15,242)	3,120	(38,490)
Net earnings	6,197	6,197
Cash dividends paid	(2,659)	(2,659)
Employee compensation and stock option plans	542	(920)			1,462
Repurchase of common stock	(1,438)				(1,438)
Other comprehensive income (loss), net of tax	(86)		(86)
Ending Balance at Apr. 04, 2021	$ 65,834	$ 116,508	$ (15,328)	$ 3,120	$ (38,466)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 1.01	$ 0.95

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 6,197	$ 5,796
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	1,894	1,747
Stock based compensation	307	263
Asset write-downs	14	11
Contingent consideration reversal	0	(983)
Net gain on sale of assets/businesses	(580)	0
Deferred tax provision	(730)	54
Credit losses and accounts receivable allowances	(13)	22
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(1,604)	(812)
Increase in inventories	(695)	(159)
Decrease in accounts payable and accrued liabilities	(2,336)	(2,523)
Decrease in other current and non-current assets	2,522	271
Decrease in other current and non-current liabilities	(902)	(329)
NET CASH FLOWS FROM OPERATING ACTIVITIES	4,074	3,358
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(677)	(625)
Proceeds from the disposal of assets/businesses, net (Note 10)	603	17
Acquisitions, net of cash acquired (Note 10)	0	(939)
Purchases of investments	(5,994)	(2,064)
Sales of investments	5,233	1,544
Credit support agreements activity, net	751	1,743
Other (primarily licenses and milestones)	(101)	(257)
NET CASH USED BY INVESTING ACTIVITIES	(185)	(581)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(2,659)	(2,505)
Repurchase of common stock	(1,438)	(1,711)
Proceeds from short-term debt	23	10
Repayment of short-term debt	(475)	(18)
Proceeds from long-term debt, net of issuance costs	1	0
Repayment of long-term debt	(1,001)	(11)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	236	332
Credit support agreements activity, net	212	0
Other	(24)	(412)
NET CASH USED BY FINANCING ACTIVITIES	(5,125)	(4,315)
Effect of exchange rate changes on cash and cash equivalents	(78)	(237)
Decrease in cash and cash equivalents	(1,314)	(1,775)
Cash and Cash equivalents, beginning of period	13,985	17,305
CASH AND CASH EQUIVALENTS, END OF PERIOD	12,671	15,530
Acquisitions
Fair value of assets acquired	0	1,136
Fair value of liabilities assumed and noncontrolling interests	0	(197)
Net cash paid for acquisitions	$ 0	$ 939

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Statement of Comprehensive Income [Abstract]
Foreign Currency Translation	$ (319)	$ 46
Securities		1
Employee Benefit Plans	(66)	(56)
Derivatives & Hedges	$ (157)	$ 256

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Apr. 04, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company’s on-going vaccine development and distribution efforts. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company. Recently Adopted Accounting Standards There were no new material accounting standards adopted in the fiscal first quarter of 2021. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Inventories

Inventories	3 Months Ended
	Apr. 04, 2021
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) April 4, 2021 January 3, 2021 Raw materials and supplies $ 1,557 1,410 Goods in process 2,034 2,040 Finished goods 6,361 5,894 Total inventories $ 9,952 9,344

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Apr. 04, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) April 4, 2021 January 3, 2021 Intangible assets with definite lives: Patents and trademarks — gross $ 39,505 39,990 Less accumulated amortization 18,006 17,618 Patents and trademarks — net 21,499 22,372 Customer relationships and other intangibles — gross 22,793 22,898 Less accumulated amortization 11,031 10,912 Customer relationships and other intangibles — net* 11,762 11,986 Intangible assets with indefinite lives: Trademarks 7,061 7,195 Purchased in-process research and development 10,788 11,849 Total intangible assets with indefinite lives 17,849 19,044 Total intangible assets — net $ 51,110 53,402 *The majority is comprised of customer relationships Goodwill as of April 4, 2021 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 Goodwill, related to acquisitions and divestitures — — — — Currency translation/Other (310) (262) (133) (705) Goodwill at April 4, 2021 $ 10,026 10,747 14,915 35,688 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.2 billion and $1.1 billion for the fiscal first quarters ended April 4, 2021 and March 29, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2021 2022 2023 2024 2025 $4,600 4,400 4,300 4,100 3,300 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 04, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTSThe Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April 4, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $102 million net, primarily related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April 4, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $41.2 billion and $31.2 billion, respectively. As of January 3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of April 4, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $57 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax: April 4, 2021 March 29, 2020 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 40 — — — — 40 — Amount of gain or (loss) recognized in AOCI — — — 40 — — — — 40 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 17 34 (113) — 3 9 (173) (110) — (2) Amount of gain or (loss) recognized in AOCI (3) (193) (76) — 17 11 302 (110) — (36) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 92 — — — 98 — Amount of gain or (loss) recognized in AOCI $ — — — (307) — — — — 625 — The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters 2021 and 2020: Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended Derivatives Not Designated as Hedging Instruments April 4, 2021 March 29, 2020 Foreign Exchange Contracts Other (income) expense $ (16) 89 The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) April 4, 2021 March 29, 2020 April 4, 2021 March 29, 2020 Debt $ 209 46 Interest (income) expense — — Cross Currency interest rate swaps $ 361 827 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) January 3, 2021 April 4, 2021 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,481 (36) 7 1,452 1,452 Equity Investments without readily determinable value $ 738 (55) 81 764 764 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $55 million of the decrease in the fair value reflected in net income were the result of impairments. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of April 4, 2021 and January 3, 2021 were as follows: April 4, 2021 January 3, 2021 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 561 — 561 849 Interest rate contracts (2) — 522 — 522 240 Total — 1,083 — 1,083 1,089 Liabilities: Forward foreign exchange contracts — 565 — 565 702 Interest rate contracts (2) — 540 — 540 1,569 Total — 1,105 — 1,105 2,271 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 51 — 51 49 Liabilities: Forward foreign exchange contracts — 43 — 43 38 Other Investments: Equity investments (3) 1,452 — — 1,452 1,481 Debt securities (4) — 14,493 — 14,493 14,042 Other Liabilities Contingent consideration (5) $ — — 600 600 633 Gross to Net Derivative Reconciliation April 4, 2021 January 3, 2021 (Dollars in Millions) Total Gross Assets $ 1,134 1,138 Credit Support Agreement (CSA) (1,028) (1,107) Total Net Asset 106 31 Total Gross Liabilities 1,148 2,309 Credit Support Agreement (CSA) (1,130) (2,172) Total Net Liabilities $ 18 137 Summarized information about changes in liabilities for contingent consideration is as follows: April 4, 2021 March 29, 2020 (Dollars in Millions) Beginning Balance $ 633 $ 1,715 Changes in estimated fair value (6) 15 (977) Additions — 106 Payments (48) (60) Ending Balance $ 600 $ 784 (1) 2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Includes $589 million and $594 million, classified as non-current other liabilities as of April 4, 2021 and January 3, 2021, respectively. Includes $11 million and $39 million classified as current liabilities as of April 4, 2021 and January 3, 2021, respectively. (6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. The Company recorded a contingent consideration reversal of $983 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net. The Company's cash, cash equivalents and current marketable securities as of April 4, 2021 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,247 — — 2,247 2,247 Non-U.S. sovereign securities (1) 400 — — 400 — 400 U.S. reverse repurchase agreements 1,199 — — 1,199 1,199 — Other reverse repurchase agreements — — — — — Corporate debt securities (1) 3,239 — — 3,239 1,890 1,349 Money market funds 2,094 — — 2,094 2,094 Time deposits (1) 947 — — 947 947 Subtotal 10,126 — — 10,126 8,377 1,749 Unrealized Gain Unrealized Loss U.S. Gov't securities 14,228 1 — 14,229 4,268 9,961 Other sovereign securities 8 — — 8 1 7 Corporate debt securities 256 — — 256 25 231 Subtotal available for sale debt (2) $ 14,492 1 — 14,493 4,294 10,199 Total cash, cash equivalents and current marketable securities $ 24,618 1 — 24,619 12,671 11,948 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. In the fiscal year ended January 3, 2021 the carrying amount was approximately the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of April 4, 2021 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 14,486 14,487 Due after one year through five years 6 6 Due after five years through ten years — — Total debt securities $ 14,492 14,493 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 4, 2021: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 3,350 3,380 Non-Current Debt 6.73% Debentures due 2023 250 292 3.375% Notes due 2023 802 868 2.05% Notes due 2023 499 515 0.650% Notes due 2024 (750MM Euro 1.1757) 880 904 5.50% Notes due 2024 (500 MM GBP 1.3799) 687 808 2.625% Notes due 2025 749 797 0.55% Notes due 2025 996 982 2.45% Notes due 2026 1,994 2,115 2.95% Notes due 2027 997 1,084 0.95% Notes due 2027 1,494 1,445 2.90% Notes due 2028 1,495 1,616 1.150% Notes due 2028 (750MM Euro 1.1757) 876 955 6.95% Notes due 2029 297 416 1.30% Notes due 2030 1,743 1,642 4.95% Debentures due 2033 498 639 4.375% Notes due 2033 855 1,046 1.650% Notes due 2035 (1.5B Euro 1.1757) 1,749 2,035 3.55% Notes due 2036 990 1,117 5.95% Notes due 2037 992 1,422 3.625% Notes due 2037 1,488 1,694 3.40% Notes due 2038 991 1,097 5.85% Debentures due 2038 696 992 4.50% Debentures due 2040 539 676 2.10% Notes due 2040 986 907 4.85% Notes due 2041 297 385 4.50% Notes due 2043 496 628 3.70% Notes due 2046 1,974 2,257 3.75% Notes due 2047 992 1,146 3.50% Notes due 2048 742 827 2.25% Notes due 2050 984 883 2.45% Notes due 2060 1,228 1,104 Other 7 6 Total Non-Current Debt $ 30,263 33,300 The weighted average effective interest rate on non-current debt is 2.98%. The excess of the estimated fair value over the carrying value of debt was $5.4 billion at January 4, 2021. The current debt balance as of April 4, 2021 includes $0.3 billion of commercial paper which has a weighted average interest rate of 0.12% and a weighted average maturity of two months. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	3 Months Ended
	Apr. 04, 2021
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal first quarters of 2021 and 2020 were 16.6% an d 11.0%, respectively. In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021. During the fiscal first quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes (1.3% net benefit to the effective tax rate). In the first fiscal quarter of 2020, the Company reversed a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the effective tax rate by 1.9% (for additional details see Note 18 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021). Additionally, the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions, as compared to the same period in the prior fiscal year. The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. As of April 4, 2021, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	3 Months Ended
	Apr. 04, 2021
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal First Quarter Ended Retirement Plans Other Benefit Plans (Dollars in Millions) April 4, 2021 March 29, 2020 April 4, 2021 March 29, 2020 Service cost $ 353 326 77 72 Interest cost 193 240 20 33 Expected return on plan assets (680) (614) (2) (2) Amortization of prior service cost/(credit) (45) — (8) (8) Recognized actuarial losses 314 223 38 36 Curtailments and settlements 1 19 — — Net periodic benefit cost $ 136 194 125 131 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the Three Months Ended April 4, 2021, the Company contributed $24 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Apr. 04, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 3, 2021 $ (8,938) 1 (6,957) 652 (15,242) Net change 276 — 233 (595) (86) April 4, 2021 $ (8,662) 1 (6,724) 57 (15,328) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 04, 2021
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal First Quarter Ended (Shares in Millions) April 4, 2021 March 29, 2020 Basic net earnings per share $ 2.35 2.20 Average shares outstanding — basic 2,631.6 2,633.7 Potential shares exercisable under stock option plans 128.4 126.0 Less: shares which could be repurchased under treasury stock method (87.3) (89.4) Convertible debt shares — 0.7 Average shares outstanding — diluted 2,672.7 2,671.0 Diluted net earnings per share $ 2.32 2.17 The diluted net earnings per share calculation for the fiscal first quarter ended April 4, 2021 excluded 9 million shares related to stock options, as the exercise price of these options was greater than their average market value. In the fiscal first quarter ended April 4, 2021, the Company did not have convertible debt.

Segments of Business and Geogra

Segments of Business and Geographic Areas	3 Months Ended
	Mar. 29, 2020
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal First Quarter Ended (Dollars in Millions) April 4, March 29, Percent Consumer Health OTC U.S. $ 599 689 (13.0) % International 575 659 (12.8) Worldwide 1,175 1,348 (12.9) Skin Health/Beauty U.S. 634 659 (3.9) International 529 458 15.7 Worldwide 1,163 1,117 4.1 Oral Care U.S. 163 176 (7.2) International 254 219 16.0 Worldwide 417 395 5.7 Baby Care U.S. 96 92 4.2 International 293 269 8.9 Worldwide 389 361 7.7 Women's Health U.S. 3 4 (25.8) International 219 228 (3.9) Worldwide 222 232 (4.3) Wound Care/Other U.S. 115 119 (3.0) International 61 52 17.6 Worldwide 177 171 3.3 TOTAL Consumer Health U.S. 1,611 1,740 (7.4) International 1,932 1,885 2.5 Worldwide 3,543 3,625 (2.3) PHARMACEUTICAL Immunology U.S. 2,413 2,410 0.1 International 1,501 1,228 22.3 Worldwide 3,914 3,638 7.6 REMICADE ® U.S. 489 625 (21.7) U.S. Exports 57 110 (48.4) International 232 256 (9.4) Worldwide 777 990 (21.5) SIMPONI / SIMPONI ARIA ® U.S. 255 272 (5.9) International 307 258 18.9 Worldwide 562 529 6.2 STELARA ® U.S. 1,331 1,217 9.4 International 817 603 35.6 Worldwide 2,148 1,819 18.1 TREMFYA ® U.S. 274 187 46.3 International 143 109 32.0 Worldwide 418 296 41.0 OTHER IMMUNOLOGY U.S. 7 — * International 2 3 (38.4) Worldwide 8 3 * Infectious Diseases U.S. 512 436 17.4 International 494 483 2.3 Worldwide 1,007 920 9.5 COVID-19 vaccine U.S. 100 — * International — — — Worldwide 100 — * EDURANT ® / rilpivirine U.S. 10 12 (12.3) International 233 212 9.8 Worldwide 243 224 8.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 380 396 (3.8) International 166 184 (9.9) Worldwide 546 579 (5.8) OTHER INFECTIOUS DISEASES U.S. 21 29 (27.0) International 96 87 9.7 Worldwide 117 116 0.6 Neuroscience U.S. 771 748 3.2 International 949 910 4.3 Worldwide 1,721 1,658 3.8 CONCERTA ® / methylphenidate U.S. 47 52 (9.6) International 123 118 4.5 Worldwide 171 171 0.2 INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 589 544 8.3 International 376 339 11.0 Worldwide 965 883 9.4 RISPERDAL CONSTA ® U.S. 67 76 (11.8) International 89 94 (4.8) Worldwide 157 170 (7.9) OTHER NEUROSCIENCE U.S. 67 75 (9.8) International 361 360 0.2 Worldwide 428 435 (1.5) Oncology U.S. 1,377 1,175 17.2 International 2,193 1,839 19.3 Worldwide 3,570 3,013 18.5 DARZALEX ® U.S. 691 463 49.2 International 674 474 42.2 Worldwide 1,365 937 45.6 ERLEADA ® U.S. 171 119 44.0 International 90 24 * Worldwide 261 143 82.8 IMBRUVICA ® U.S. 444 432 2.8 International 680 599 13.5 Worldwide 1,125 1,031 9.0 ZYTIGA ® / abiraterone acetate U.S. 50 139 (64.2) International 588 552 6.6 Worldwide 638 690 (7.6) OTHER ONCOLOGY (1) U.S. 21 22 (5.1) International 161 190 (15.3) Worldwide 182 212 (14.2) Pulmonary Hypertension U.S. 573 486 18.0 International 288 260 10.8 Worldwide 861 745 15.5 OPSUMIT ® U.S. 272 229 18.5 International 179 160 11.5 Worldwide 450 389 15.6 UPTRAVI ® U.S. 259 212 21.9 International 46 38 23.0 Worldwide 305 250 22.0 OTHER PULMONARY HYPERTENSION U.S. 42 44 (3.5) International 63 62 1.4 Worldwide 105 106 (0.6) Cardiovascular / Metabolism / Other U.S. 799 806 (0.9) International 328 354 (7.2) Worldwide 1,127 1,160 (2.8) XARELTO ® U.S. 589 527 11.7 International — — — Worldwide 589 527 11.7 INVOKANA ® / INVOKAMET ® U.S. 87 117 (26.1) International 63 58 9.2 Worldwide 150 175 (14.4) PROCRIT ® / EPREX ® U.S. 62 76 (18.3) International 64 79 (18.1) Worldwide 127 155 (18.2) OTHER U.S. 60 85 (28.8) International 201 217 (7.7) Worldwide 261 302 (13.6) TOTAL PHARMACEUTICAL U.S. 6,446 6,061 6.4 International 5,753 5,073 13.4 Worldwide 12,199 11,134 9.6 MEDICAL DEVICES Interventional Solutions U.S. 434 365 19.0 International 514 362 42.0 Worldwide 949 727 30.4 Orthopaedics U.S. 1,249 1,250 (0.1) International 864 788 9.7 Worldwide 2,113 2,038 3.7 HIPS U.S. 210 206 2.4 International 146 132 11.2 Worldwide 357 337 5.8 KNEES U.S. 185 214 (13.5) International 132 130 2.0 Worldwide 317 343 (7.6) TRAUMA U.S. 450 407 10.7 International 282 247 14.4 Worldwide 733 654 12.1 SPINE, SPORTS & OTHER U.S. 403 423 (4.8) International 303 280 8.4 Worldwide 706 703 0.4 Surgery U.S. 898 844 6.5 International 1,474 1,257 17.3 Worldwide 2,372 2,100 12.9 ADVANCED U.S. 405 381 6.5 International 713 567 25.7 Worldwide 1,118 948 18.0 GENERAL U.S. 493 463 6.5 International 761 690 10.3 Worldwide 1,254 1,153 8.8 Vision U.S. 472 439 7.4 International 673 628 7.3 Worldwide 1,145 1,067 7.3 CONTACT LENSES / OTHER U.S. 371 346 7.2 International 486 467 4.0 Worldwide 857 814 5.3 SURGICAL U.S. 101 93 8.2 International 187 160 17.0 Worldwide 288 253 13.7 TOTAL MEDICAL DEVICES U.S. 3,054 2,898 5.4 International 3,525 3,034 16.2 Worldwide 6,579 5,932 10.9 WORLDWIDE U.S. 11,111 10,699 3.9 International 11,210 9,992 12.2 Worldwide $ 22,321 20,691 7.9 % *Percentage greater than 100% or not meaningful (1) Inclusive of VELCADE ® which was previously disclosed separately EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal First Quarter Ended (Dollars in Millions) April 4, March 29, Percent Consumer Health (1) $ 788 770 2.3% Pharmaceutical (2) 5,223 3,834 36.2 Medical Devices (3) 1,629 2,025 (19.6) Segment earnings before provision for taxes 7,640 6,629 15.3 Less: Expense not allocated to segments (4) 211 120 Worldwide income before tax $ 7,429 6,509 14.1% (1) Consumer Health • Includes amortization expense of $0.1 billion in both the fiscal first quarter of 2021 and 2020. (2) Pharmaceutical • Includes divestiture gains of $0.6 billion in the fiscal first quarter of 2021 related to two brands outside the U.S. • Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020. • Includes litigation expense of $0.1 billion in the fiscal first quarter of 2020. • Includes amortization expense of $0.9 billion and $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively. In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) Medical Devices • Includes a contingent consideration reversal of $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively. • Includes amortization expense of $0.3 billion and $0.2 billion in the fiscal first quarter of 2021 and 2020, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal First Quarter Ended (Dollars in Millions) April 4, 2021 March 29, 2020 Percent United States $ 11,111 10,699 3.9 % Europe 5,414 4,827 12.1 Western Hemisphere, excluding U.S. 1,424 1,502 (5.1) Asia-Pacific, Africa 4,372 3,663 19.4 Total $ 22,321 20,691 7.9 %

Acquisitions and Divestitures

Acquisitions and Divestitures	3 Months Ended
	Apr. 04, 2021
Business Combinations [Abstract]
Acquisitions and Divestitures	ACQUISITIONS AND DIVESTITURESIn the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6 billion. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Apr. 04, 2021
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April 4, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of April 4, 2021, in the United States there were approximately 300 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 7,000 with respect to the PINNACLE ® Acetabular Cup System; 12,200 with respect to pelvic meshes; 9,200 with respect to RISPERDAL ® ; 10,200 with respect to XARELTO ® ; 28,900 with respect to body powders containing talc; 300 with respect to INVOKANA ® ; and 4,400 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country . The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada,. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials. Claims have also been filed against Ethicon and Johnson & Johnson alleging personal injuries arising from the PROCEED ® Mesh and PROCEED ® Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. Ethicon and Johnson & Johnson also have been subject to claims for personal injuries arising from the PROLENE™ Polypropylene Hernia System (PHS). In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PHS cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. There are now approximately 304 cases pending in the MCL and discovery is underway in a subset of these cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch, and PROLENE™ Polypropylene Hernia System products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff which the trial judge reduced to $6.8 million in January 2020. The Company and plaintiff each are appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI’s collaboration partner for XARELTO ® , Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson & Johnson announced an agreement in principle to settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits primarily have been filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied plaintiffs’ attempt to limit the scope of testimony of certain of the Company’s witnesses. With this ruling made, case-specific discovery has begun per the Court’s directive. In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion and, with additional interest as of April 4, 2021, as the Company pursues further appeal, is approximately $2.5 billion (the Ingham decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied. In March 2021, the Company filed a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court. In April 2021, the Plaintiffs filed their opposition to the petition. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the Ingham decision currently on appeal , in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company’s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company’s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants’ committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements. The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus’s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent’s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates, allowing Debtors Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Debtors’ Plan and opted out of the consensual releases in the Plan. Discovery with respect to the Debtors’ Plan is ongoing and the Confirmation Hearing is set for August 2021. Relatedly, in February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and Cyprus filed its Disclosure Statement and Plan. Also, in February 2021, several of the Company’s insurers involved in coverage litigation in New Jersey State Court (the “Coverage Action”) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In March 2021 briefing on Plaintiffs’ motion for class certification was completed. Discovery is ongoing. In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation . In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th e In re Johnson & Johnson Talc Stockholder Derivative Litigation . The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson & Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson & Johnson’s motion to dismiss pending a decision on Plaintiff’s motion for discovery. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants’ motion was complete. In February 2021, the Court granted Defendants’ motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act (CLRA) relating to JOHNSON’S ® Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company’s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson & Johnson and Johnson & Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing on the motion was held in April 2021. Limited informal discovery is continuing. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of ELMIRON ® , a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON ® contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON ® related product liability litigation. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below. Medical Devices In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412. Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021. In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® PDS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 (’296) and 7,033,603 (’603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020, the USPTO denied institution of the ’296 patent IPR and granted institution of the ’603 p

Restructuring

Restructuring	3 Months Ended
	Apr. 04, 2021
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2021, the Company recorded a pre-tax charge of $104 million, which is included on the following lines of the Consolidated Statement of Earnings, $53 million in restructuring, $27 million in cost of products sold and $24 million in other (income) expense, net. Total project costs of approximately $1.4 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, January 3, 2021 $ 135 — 9 144 Current year activity: Charges — 14 90 104 Cash payments (5) — (91) (96) Settled non cash — (14) (14) Reserve balance, April 4, 2021 (1) $ 130 — 8 138 (1) Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 04, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company’s on-going vaccine development and distribution efforts. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
New Accounting Standards Recently Adopted	New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company. Recently Adopted Accounting Standards There were no new material accounting standards adopted in the fiscal first quarter of 2021.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Apr. 04, 2021
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) April 4, 2021 January 3, 2021 Raw materials and supplies $ 1,557 1,410 Goods in process 2,034 2,040 Finished goods 6,361 5,894 Total inventories $ 9,952 9,344

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Apr. 04, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) April 4, 2021 January 3, 2021 Intangible assets with definite lives: Patents and trademarks — gross $ 39,505 39,990 Less accumulated amortization 18,006 17,618 Patents and trademarks — net 21,499 22,372 Customer relationships and other intangibles — gross 22,793 22,898 Less accumulated amortization 11,031 10,912 Customer relationships and other intangibles — net* 11,762 11,986 Intangible assets with indefinite lives: Trademarks 7,061 7,195 Purchased in-process research and development 10,788 11,849 Total intangible assets with indefinite lives 17,849 19,044 Total intangible assets — net $ 51,110 53,402 *The majority is comprised of customer relationships
Goodwill	Goodwill as of April 4, 2021 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 Goodwill, related to acquisitions and divestitures — — — — Currency translation/Other (310) (262) (133) (705) Goodwill at April 4, 2021 $ 10,026 10,747 14,915 35,688
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2021 2022 2023 2024 2025 $4,600 4,400 4,300 4,100 3,300

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 04, 2021
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax: April 4, 2021 March 29, 2020 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 40 — — — — 40 — Amount of gain or (loss) recognized in AOCI — — — 40 — — — — 40 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 17 34 (113) — 3 9 (173) (110) — (2) Amount of gain or (loss) recognized in AOCI (3) (193) (76) — 17 11 302 (110) — (36) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 92 — — — 98 — Amount of gain or (loss) recognized in AOCI $ — — — (307) — — — — 625 — The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) April 4, 2021 March 29, 2020 April 4, 2021 March 29, 2020 Debt $ 209 46 Interest (income) expense — — Cross Currency interest rate swaps $ 361 827 Interest (income) expense — —
Schedule of Effect of Derivatives not Designated as Hedging Instruments	Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended Derivatives Not Designated as Hedging Instruments April 4, 2021 March 29, 2020 Foreign Exchange Contracts Other (income) expense $ (16) 89
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) January 3, 2021 April 4, 2021 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,481 (36) 7 1,452 1,452 Equity Investments without readily determinable value $ 738 (55) 81 764 764 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of April 4, 2021 and January 3, 2021 were as follows: April 4, 2021 January 3, 2021 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 561 — 561 849 Interest rate contracts (2) — 522 — 522 240 Total — 1,083 — 1,083 1,089 Liabilities: Forward foreign exchange contracts — 565 — 565 702 Interest rate contracts (2) — 540 — 540 1,569 Total — 1,105 — 1,105 2,271 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 51 — 51 49 Liabilities: Forward foreign exchange contracts — 43 — 43 38 Other Investments: Equity investments (3) 1,452 — — 1,452 1,481 Debt securities (4) — 14,493 — 14,493 14,042 Other Liabilities Contingent consideration (5) $ — — 600 600 633 Gross to Net Derivative Reconciliation April 4, 2021 January 3, 2021 (Dollars in Millions) Total Gross Assets $ 1,134 1,138 Credit Support Agreement (CSA) (1,028) (1,107) Total Net Asset 106 31 Total Gross Liabilities 1,148 2,309 Credit Support Agreement (CSA) (1,130) (2,172) Total Net Liabilities $ 18 137 Summarized information about changes in liabilities for contingent consideration is as follows: April 4, 2021 March 29, 2020 (Dollars in Millions) Beginning Balance $ 633 $ 1,715 Changes in estimated fair value (6) 15 (977) Additions — 106 Payments (48) (60) Ending Balance $ 600 $ 784 (1) 2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Includes $589 million and $594 million, classified as non-current other liabilities as of April 4, 2021 and January 3, 2021, respectively. Includes $11 million and $39 million classified as current liabilities as of April 4, 2021 and January 3, 2021, respectively. (6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of April 4, 2021 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,247 — — 2,247 2,247 Non-U.S. sovereign securities (1) 400 — — 400 — 400 U.S. reverse repurchase agreements 1,199 — — 1,199 1,199 — Other reverse repurchase agreements — — — — — Corporate debt securities (1) 3,239 — — 3,239 1,890 1,349 Money market funds 2,094 — — 2,094 2,094 Time deposits (1) 947 — — 947 947 Subtotal 10,126 — — 10,126 8,377 1,749 Unrealized Gain Unrealized Loss U.S. Gov't securities 14,228 1 — 14,229 4,268 9,961 Other sovereign securities 8 — — 8 1 7 Corporate debt securities 256 — — 256 25 231 Subtotal available for sale debt (2) $ 14,492 1 — 14,493 4,294 10,199 Total cash, cash equivalents and current marketable securities $ 24,618 1 — 24,619 12,671 11,948 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of April 4, 2021 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 14,486 14,487 Due after one year through five years 6 6 Due after five years through ten years — — Total debt securities $ 14,492 14,493
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 4, 2021: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 3,350 3,380 Non-Current Debt 6.73% Debentures due 2023 250 292 3.375% Notes due 2023 802 868 2.05% Notes due 2023 499 515 0.650% Notes due 2024 (750MM Euro 1.1757) 880 904 5.50% Notes due 2024 (500 MM GBP 1.3799) 687 808 2.625% Notes due 2025 749 797 0.55% Notes due 2025 996 982 2.45% Notes due 2026 1,994 2,115 2.95% Notes due 2027 997 1,084 0.95% Notes due 2027 1,494 1,445 2.90% Notes due 2028 1,495 1,616 1.150% Notes due 2028 (750MM Euro 1.1757) 876 955 6.95% Notes due 2029 297 416 1.30% Notes due 2030 1,743 1,642 4.95% Debentures due 2033 498 639 4.375% Notes due 2033 855 1,046 1.650% Notes due 2035 (1.5B Euro 1.1757) 1,749 2,035 3.55% Notes due 2036 990 1,117 5.95% Notes due 2037 992 1,422 3.625% Notes due 2037 1,488 1,694 3.40% Notes due 2038 991 1,097 5.85% Debentures due 2038 696 992 4.50% Debentures due 2040 539 676 2.10% Notes due 2040 986 907 4.85% Notes due 2041 297 385 4.50% Notes due 2043 496 628 3.70% Notes due 2046 1,974 2,257 3.75% Notes due 2047 992 1,146 3.50% Notes due 2048 742 827 2.25% Notes due 2050 984 883 2.45% Notes due 2060 1,228 1,104 Other 7 6 Total Non-Current Debt $ 30,263 33,300

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	3 Months Ended
	Apr. 04, 2021
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal First Quarter Ended Retirement Plans Other Benefit Plans (Dollars in Millions) April 4, 2021 March 29, 2020 April 4, 2021 March 29, 2020 Service cost $ 353 326 77 72 Interest cost 193 240 20 33 Expected return on plan assets (680) (614) (2) (2) Amortization of prior service cost/(credit) (45) — (8) (8) Recognized actuarial losses 314 223 38 36 Curtailments and settlements 1 19 — — Net periodic benefit cost $ 136 194 125 131

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Apr. 04, 2021
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 3, 2021 $ (8,938) 1 (6,957) 652 (15,242) Net change 276 — 233 (595) (86) April 4, 2021 $ (8,662) 1 (6,724) 57 (15,328)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 04, 2021
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal First Quarter Ended (Shares in Millions) April 4, 2021 March 29, 2020 Basic net earnings per share $ 2.35 2.20 Average shares outstanding — basic 2,631.6 2,633.7 Potential shares exercisable under stock option plans 128.4 126.0 Less: shares which could be repurchased under treasury stock method (87.3) (89.4) Convertible debt shares — 0.7 Average shares outstanding — diluted 2,672.7 2,671.0 Diluted net earnings per share $ 2.32 2.17

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal First Quarter Ended (Dollars in Millions) April 4, March 29, Percent Consumer Health OTC U.S. $ 599 689 (13.0) % International 575 659 (12.8) Worldwide 1,175 1,348 (12.9) Skin Health/Beauty U.S. 634 659 (3.9) International 529 458 15.7 Worldwide 1,163 1,117 4.1 Oral Care U.S. 163 176 (7.2) International 254 219 16.0 Worldwide 417 395 5.7 Baby Care U.S. 96 92 4.2 International 293 269 8.9 Worldwide 389 361 7.7 Women's Health U.S. 3 4 (25.8) International 219 228 (3.9) Worldwide 222 232 (4.3) Wound Care/Other U.S. 115 119 (3.0) International 61 52 17.6 Worldwide 177 171 3.3 TOTAL Consumer Health U.S. 1,611 1,740 (7.4) International 1,932 1,885 2.5 Worldwide 3,543 3,625 (2.3) PHARMACEUTICAL Immunology U.S. 2,413 2,410 0.1 International 1,501 1,228 22.3 Worldwide 3,914 3,638 7.6 REMICADE ® U.S. 489 625 (21.7) U.S. Exports 57 110 (48.4) International 232 256 (9.4) Worldwide 777 990 (21.5) SIMPONI / SIMPONI ARIA ® U.S. 255 272 (5.9) International 307 258 18.9 Worldwide 562 529 6.2 STELARA ® U.S. 1,331 1,217 9.4 International 817 603 35.6 Worldwide 2,148 1,819 18.1 TREMFYA ® U.S. 274 187 46.3 International 143 109 32.0 Worldwide 418 296 41.0 OTHER IMMUNOLOGY U.S. 7 — * International 2 3 (38.4) Worldwide 8 3 * Infectious Diseases U.S. 512 436 17.4 International 494 483 2.3 Worldwide 1,007 920 9.5 COVID-19 vaccine U.S. 100 — * International — — — Worldwide 100 — * EDURANT ® / rilpivirine U.S. 10 12 (12.3) International 233 212 9.8 Worldwide 243 224 8.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 380 396 (3.8) International 166 184 (9.9) Worldwide 546 579 (5.8) OTHER INFECTIOUS DISEASES U.S. 21 29 (27.0) International 96 87 9.7 Worldwide 117 116 0.6 Neuroscience U.S. 771 748 3.2 International 949 910 4.3 Worldwide 1,721 1,658 3.8 CONCERTA ® / methylphenidate U.S. 47 52 (9.6) International 123 118 4.5 Worldwide 171 171 0.2 INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 589 544 8.3 International 376 339 11.0 Worldwide 965 883 9.4 RISPERDAL CONSTA ® U.S. 67 76 (11.8) International 89 94 (4.8) Worldwide 157 170 (7.9) OTHER NEUROSCIENCE U.S. 67 75 (9.8) International 361 360 0.2 Worldwide 428 435 (1.5) Oncology U.S. 1,377 1,175 17.2 International 2,193 1,839 19.3 Worldwide 3,570 3,013 18.5 DARZALEX ® U.S. 691 463 49.2 International 674 474 42.2 Worldwide 1,365 937 45.6 ERLEADA ® U.S. 171 119 44.0 International 90 24 * Worldwide 261 143 82.8 IMBRUVICA ® U.S. 444 432 2.8 International 680 599 13.5 Worldwide 1,125 1,031 9.0 ZYTIGA ® / abiraterone acetate U.S. 50 139 (64.2) International 588 552 6.6 Worldwide 638 690 (7.6) OTHER ONCOLOGY (1) U.S. 21 22 (5.1) International 161 190 (15.3) Worldwide 182 212 (14.2) Pulmonary Hypertension U.S. 573 486 18.0 International 288 260 10.8 Worldwide 861 745 15.5 OPSUMIT ® U.S. 272 229 18.5 International 179 160 11.5 Worldwide 450 389 15.6 UPTRAVI ® U.S. 259 212 21.9 International 46 38 23.0 Worldwide 305 250 22.0 OTHER PULMONARY HYPERTENSION U.S. 42 44 (3.5) International 63 62 1.4 Worldwide 105 106 (0.6) Cardiovascular / Metabolism / Other U.S. 799 806 (0.9) International 328 354 (7.2) Worldwide 1,127 1,160 (2.8) XARELTO ® U.S. 589 527 11.7 International — — — Worldwide 589 527 11.7 INVOKANA ® / INVOKAMET ® U.S. 87 117 (26.1) International 63 58 9.2 Worldwide 150 175 (14.4) PROCRIT ® / EPREX ® U.S. 62 76 (18.3) International 64 79 (18.1) Worldwide 127 155 (18.2) OTHER U.S. 60 85 (28.8) International 201 217 (7.7) Worldwide 261 302 (13.6) TOTAL PHARMACEUTICAL U.S. 6,446 6,061 6.4 International 5,753 5,073 13.4 Worldwide 12,199 11,134 9.6 MEDICAL DEVICES Interventional Solutions U.S. 434 365 19.0 International 514 362 42.0 Worldwide 949 727 30.4 Orthopaedics U.S. 1,249 1,250 (0.1) International 864 788 9.7 Worldwide 2,113 2,038 3.7 HIPS U.S. 210 206 2.4 International 146 132 11.2 Worldwide 357 337 5.8 KNEES U.S. 185 214 (13.5) International 132 130 2.0 Worldwide 317 343 (7.6) TRAUMA U.S. 450 407 10.7 International 282 247 14.4 Worldwide 733 654 12.1 SPINE, SPORTS & OTHER U.S. 403 423 (4.8) International 303 280 8.4 Worldwide 706 703 0.4 Surgery U.S. 898 844 6.5 International 1,474 1,257 17.3 Worldwide 2,372 2,100 12.9 ADVANCED U.S. 405 381 6.5 International 713 567 25.7 Worldwide 1,118 948 18.0 GENERAL U.S. 493 463 6.5 International 761 690 10.3 Worldwide 1,254 1,153 8.8 Vision U.S. 472 439 7.4 International 673 628 7.3 Worldwide 1,145 1,067 7.3 CONTACT LENSES / OTHER U.S. 371 346 7.2 International 486 467 4.0 Worldwide 857 814 5.3 SURGICAL U.S. 101 93 8.2 International 187 160 17.0 Worldwide 288 253 13.7 TOTAL MEDICAL DEVICES U.S. 3,054 2,898 5.4 International 3,525 3,034 16.2 Worldwide 6,579 5,932 10.9 WORLDWIDE U.S. 11,111 10,699 3.9 International 11,210 9,992 12.2 Worldwide $ 22,321 20,691 7.9 % *Percentage greater than 100% or not meaningful (1) Inclusive of VELCADE ® which was previously disclosed separately
Operating Profit by Segment of Business		EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal First Quarter Ended (Dollars in Millions) April 4, March 29, Percent Consumer Health (1) $ 788 770 2.3% Pharmaceutical (2) 5,223 3,834 36.2 Medical Devices (3) 1,629 2,025 (19.6) Segment earnings before provision for taxes 7,640 6,629 15.3 Less: Expense not allocated to segments (4) 211 120 Worldwide income before tax $ 7,429 6,509 14.1% (1) Consumer Health • Includes amortization expense of $0.1 billion in both the fiscal first quarter of 2021 and 2020. (2) Pharmaceutical • Includes divestiture gains of $0.6 billion in the fiscal first quarter of 2021 related to two brands outside the U.S. • Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020. • Includes litigation expense of $0.1 billion in the fiscal first quarter of 2020. • Includes amortization expense of $0.9 billion and $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively. In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) Medical Devices • Includes a contingent consideration reversal of $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively. • Includes amortization expense of $0.3 billion and $0.2 billion in the fiscal first quarter of 2021 and 2020, respectively.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal First Quarter Ended (Dollars in Millions) April 4, 2021 March 29, 2020 Percent United States $ 11,111 10,699 3.9 % Europe 5,414 4,827 12.1 Western Hemisphere, excluding U.S. 1,424 1,502 (5.1) Asia-Pacific, Africa 4,372 3,663 19.4 Total $ 22,321 20,691 7.9 %

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Apr. 04, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, January 3, 2021 $ 135 — 9 144 Current year activity: Charges — 14 90 104 Cash payments (5) — (91) (96) Settled non cash — (14) (14) Reserve balance, April 4, 2021 (1) $ 130 — 8 138 (1) Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Apr. 04, 2021	Jan. 03, 2021
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,557	$ 1,410
Goods in process	2,034	2,040
Finished goods	6,361	5,894
Total inventories	$ 9,952	$ 9,344

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Apr. 04, 2021	Jan. 03, 2021
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 17,849	$ 19,044
Total intangible assets - net	51,110	53,402
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	7,061	7,195
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	10,788	11,849
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	39,505	39,990
Less accumulated amortization	18,006	17,618
Finite-Lived Intangible Assets, Net	21,499	22,372
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	22,793	22,898
Less accumulated amortization	11,031	10,912
Finite-Lived Intangible Assets, Net	$ 11,762	$ 11,986

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	3 Months Ended
	Apr. 04, 2021USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 36,393
Goodwill, related to acquisitions and divestitures	0
Currency translation/Other	(705)
Goodwill End of Period	35,688
Consumer Health
Goodwill [Roll Forward]
Goodwill Beginning of Period	10,336
Goodwill, related to acquisitions and divestitures	0
Currency translation/Other	(310)
Goodwill End of Period	10,026
PHARMACEUTICAL
Goodwill [Roll Forward]
Goodwill Beginning of Period	11,009
Goodwill, related to acquisitions and divestitures	0
Currency translation/Other	(262)
Goodwill End of Period	10,747
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	15,048
Goodwill, related to acquisitions and divestitures	0
Currency translation/Other	(133)
Goodwill End of Period	$ 14,915

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense of amortizable intangible assets	$ 1.2	$ 1.1
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	21 years

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Apr. 04, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 4,600
2022	4,400
2023	4,300
2024	4,100
2025	$ 3,300

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 04, 2021	Jan. 03, 2021
Derivative [Line Items]
Accumulated other comprehensive income on derivatives, after tax	$ 57
Reclassification of foreign exchange contracts into earnings, period	next 12 months
Maximum length of time for hedge exposure	18 months
Weighted average interest rate on non-current debt	2.98%
Excess of the estimated fair value over the carrying value of debt		$ 5,400
Current Debt	$ 3,350	2,631
Commercial Paper
Derivative [Line Items]
Current Debt	$ 300
Weighted average interest rate	0.12%
Term	2 months
Forward foreign exchange contracts
Derivative [Line Items]
Collateral Already Posted, Aggregate Fair Value	$ 102
Derivative, Notional Amount	41,200	37,800
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Notional Amount	31,200	$ 30,600
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss	$ (55)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0
Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	40	40
Amount of gain or (loss) recognized in AOCI	40	40
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(3)	11
Amount of gain or (loss) reclassified from AOCI into income	17	9
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(193)	302
Amount of gain or (loss) reclassified from AOCI into income	34	(173)
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(76)	(110)
Amount of gain or (loss) reclassified from AOCI into income	(113)	(110)
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	17	(36)
Amount of gain or (loss) reclassified from AOCI into income	3	(2)
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0
Amount of gain or (loss) reclassified from AOCI into income	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(307)	625
Amount of gain or (loss) reclassified from AOCI into income	$ 92	$ 98

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ (16)	$ 89

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	$ 209	$ 46
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	361	827
Cross Currency Interest Rate Contract | Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Jan. 03, 2021
Equity Investment [Roll Forward]
Non Current Other Assets	$ 6,538	$ 6,562
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	1,481
Changes in Fair Value Reflected in Net Income	(36)
Sales/ Purchases/Other	7
Carrying value, end of period	1,452
Non Current Other Assets	1,452
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	738
Changes in Fair Value Reflected in Net Income	(55)
Sales/ Purchases/Other	81
Carrying value, end of period	764
Non Current Other Assets	$ 764

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020	Jan. 03, 2021
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 1,083
Derivatives designated as hedging instruments : Liabilities	1,105
Available-for-sale Securities, Equity Securities	1,452		$ 1,481
Available-for-sale Securities	14,493		14,042
Contingent consideration	600		633
Total Gross Assets	1,134		1,138
Credit Support Agreement (CSA)	(1,028)		(1,107)
Total Net Asset	106		31
Total Gross Liabilities	1,148		2,309
Credit Support Agreement (CSA)	(1,130)		(2,172)
Total Net Liabilities	18		137
Beginning Balance	633	$ 1,715
Changes in estimated fair value (6)	15	(977)
Additions	0	106
Payments	(48)	(60)
Ending Balance	600	784
Contingent consideration reversal	0	(983)
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	1,452		1,481
Available-for-sale Securities	0
Contingent consideration	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,083		1,089
Derivatives designated as hedging instruments : Liabilities	1,105		2,271
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	14,493
Contingent consideration	0
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Contingent consideration	600		633
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	522
Derivatives designated as hedging instruments : Liabilities	540
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	522		240
Derivatives designated as hedging instruments : Liabilities	540		1,569
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	561
Derivatives designated as hedging instruments : Liabilities	565
Derivatives not designated as hedging instruments : Assets	51
Derivatives not designated as hedging instruments : Liabilities	43
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	561		849
Derivatives designated as hedging instruments : Liabilities	565		702
Derivatives not designated as hedging instruments : Assets	51		49
Derivatives not designated as hedging instruments : Liabilities	43		38
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Auris Health
Financial assets and liabilities at fair value
Contingent consideration reversal		$ (983)
Other Noncurrent Liabilities | Auris Health
Financial assets and liabilities at fair value
Contingent consideration	589		594
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration	$ 11		$ 39

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Apr. 04, 2021	Jan. 03, 2021
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 14,493	$ 14,042
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	12,671	13,985
Marketable securities	11,948	$ 11,200
Total cash, cash equivalents and current marketable securities, Carrying Amount	24,618
Total cash, cash equivalents and current marketable securities, Unrecognized Gain	1
Total cash, cash equivalents and current marketable securities, Unrecognized Loss	0
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	24,619
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	10,126
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	10,126
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	8,377
Marketable securities	1,749
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,247
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,247
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,247
Held-to-maturity Securities | Non-U.S. sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	400
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	400
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	400
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,199
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,199
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,199
Marketable securities	0
Held-to-maturity Securities | Other reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	0
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	3,239
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	3,239
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,890
Marketable securities	1,349
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,094
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,094
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,094
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	947
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	947
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	947
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	14,492
Available-for-sale Securities, Unrecognized Gain	1
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	14,493
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,294
Marketable securities	10,199
Available-for-sale Securities | Non-U.S. sovereign securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	8
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	8
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1
Marketable securities	7
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	256
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	256
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	25
Marketable securities	231
Available-for-sale Securities | U.S. Gov't securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	14,228
Available-for-sale Securities, Unrecognized Gain	1
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	14,229
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,268
Marketable securities	$ 9,961

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Apr. 04, 2021USD ($)
Cost Basis
Due within one year	$ 14,486
Due after one year through five years	6
Due after five years through ten years	0
Total debt securities	14,492
Fair Value
Due within one year	14,487
Due after one year through five years	6
Due after five years through ten years	0
Total debt securities	$ 14,493

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Apr. 04, 2021	Jan. 03, 2021
Financial Liabilities
Current Debt	$ 3,350	$ 2,631
Non-Current Debt
Non-Current Debt	30,263	$ 32,635
Carrying Amount
Financial Liabilities
Current Debt	3,350
Non-Current Debt
Non-Current Debt	30,263
Estimated Fair Value
Financial Liabilities
Current Debt	3,380
Non-Current Debt
Non-Current Debt	$ 33,300
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 292
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 802
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 868
2.05% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 499
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 515
0.650% Notes due 2024 (750MM Euro 1.1757)
Non-Current Debt
Stated interest rate (as a percent)	0.65%
0.650% Notes due 2024 (750MM Euro 1.1757) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 880
0.650% Notes due 2024 (750MM Euro 1.1757) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 904
5.50% Notes due 2024 (500 MM GBP 1.3799)
Non-Current Debt
Stated interest rate (as a percent)	5.50%
5.50% Notes due 2024 (500 MM GBP 1.3799) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 687
5.50% Notes due 2024 (500 MM GBP 1.3799) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 808
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 749
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 797
0.55% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	0.55%
0.55% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 996
0.55% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 982
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,994
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,115
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,084
0.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	0.95%
0.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,494
0.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,445
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,495
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,616
1.150% Notes due 2028 (750MM Euro 1.1757)
Non-Current Debt
Stated interest rate (as a percent)	1.15%
1.150% Notes due 2028 (750MM Euro 1.1757) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 876
1.150% Notes due 2028 (750MM Euro 1.1757) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 955
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 416
1.30% Notes due 2030
Non-Current Debt
Stated interest rate (as a percent)	1.30%
1.30% Notes due 2030 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,743
1.30% Notes due 2030 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,642
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 639
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 855
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,046
1.650% Notes due 2035 (1.5B Euro 1.1757)
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.650% Notes due 2035 (1.5B Euro 1.1757) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,749
1.650% Notes due 2035 (1.5B Euro 1.1757) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,035
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 990
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,117
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,422
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,488
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,694
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,097
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 696
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 992
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 539
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 676
2.10% Notes due 2040
Non-Current Debt
Stated interest rate (as a percent)	2.10%
2.10% Notes due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 986
2.10% Notes due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 907
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 385
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 496
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 628
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,974
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,257
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,146
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 742
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 827
2.25% Notes due 2050
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.25% Notes due 2050 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 984
2.25% Notes due 2050 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 883
2.45% Notes due 2060
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2060 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,228
2.45% Notes due 2060 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	1,104
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	7
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 6

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Income Tax (Textuals)
Worldwide effective income tax rate (as a percent)	16.60%	11.00%
Deferred tax benefit related to TRAF		$ 0.3
Deferred tax liability related to TRAF		$ 0.2
Deferred tax benefit related to TRAF, percent		1.30%
Unrecognized tax benefits	$ 3.3
Auris Health
Income Tax (Textuals)
Net impact to tax rate due to change in contingent consideration liability		1.90%

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 353	$ 326
Interest cost	193	240
Expected return on plan assets	(680)	(614)
Amortization of prior service cost/(credit)	(45)	0
Recognized actuarial losses	314	223
Curtailments and settlements	1	19
Net periodic benefit cost	136	194
Other Benefit Plans
Components of net periodic benefit cost
Service cost	77	72
Interest cost	20	33
Expected return on plan assets	(2)	(2)
Amortization of prior service cost/(credit)	(8)	(8)
Recognized actuarial losses	38	36
Curtailments and settlements	0	0
Net periodic benefit cost	$ 125	$ 131

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	3 Months Ended
	Apr. 04, 2021USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 24
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 10

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 63,278	$ 59,471
Net change	(86)	(352)
Ending Balance	65,834	61,294
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(8,938)
Net change	276
Ending Balance	(8,662)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	1
Net change	0
Ending Balance	1
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(6,957)
Net change	233
Ending Balance	(6,724)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	652
Net change	(595)
Ending Balance	57
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(15,242)	(15,891)
Net change	(86)	(352)
Ending Balance	$ (15,328)	$ (16,243)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Thousands	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 2.35	$ 2.20
Average shares outstanding — basic	2,631,600	2,633,700
Potential shares exercisable under stock option plans	128,400	126,000
Less: shares which could be repurchased under treasury stock method	(87,300)	(89,400)
Convertible debt shares	0	700
Average shares outstanding — diluted	2,672,700	2,671,000
Diluted net earnings per share	$ 2.32	$ 2.17
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,000	10,000

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Sales by segment of business
Sales to customers	$ 22,321	$ 20,691
Percent Change (as a percent)	7.90%
U.S.
Sales by segment of business
Sales to customers	$ 11,111	10,699
Percent Change (as a percent)	3.90%
International
Sales by segment of business
Sales to customers	$ 11,210	9,992
Percent Change (as a percent)	12.20%
Consumer Health
Sales by segment of business
Sales to customers	$ 3,543	3,625
Percent Change (as a percent)	(2.30%)
Consumer Health | U.S.
Sales by segment of business
Sales to customers	$ 1,611	1,740
Percent Change (as a percent)	(7.40%)
Consumer Health | International
Sales by segment of business
Sales to customers	$ 1,932	1,885
Percent Change (as a percent)	2.50%
Consumer Health | OTC
Sales by segment of business
Sales to customers	$ 1,175	1,348
Percent Change (as a percent)	(12.90%)
Consumer Health | OTC | U.S.
Sales by segment of business
Sales to customers	$ 599	689
Percent Change (as a percent)	(13.00%)
Consumer Health | OTC | International
Sales by segment of business
Sales to customers	$ 575	659
Percent Change (as a percent)	(12.80%)
Consumer Health | Skin Health/Beauty
Sales by segment of business
Sales to customers	$ 1,163	1,117
Percent Change (as a percent)	4.10%
Consumer Health | Skin Health/Beauty | U.S.
Sales by segment of business
Sales to customers	$ 634	659
Percent Change (as a percent)	(3.90%)
Consumer Health | Skin Health/Beauty | International
Sales by segment of business
Sales to customers	$ 529	458
Percent Change (as a percent)	15.70%
Consumer Health | Oral Care
Sales by segment of business
Sales to customers	$ 417	395
Percent Change (as a percent)	5.70%
Consumer Health | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 163	176
Percent Change (as a percent)	(7.20%)
Consumer Health | Oral Care | International
Sales by segment of business
Sales to customers	$ 254	219
Percent Change (as a percent)	16.00%
Consumer Health | Baby Care
Sales by segment of business
Sales to customers	$ 389	361
Percent Change (as a percent)	7.70%
Consumer Health | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 96	92
Percent Change (as a percent)	4.20%
Consumer Health | Baby Care | International
Sales by segment of business
Sales to customers	$ 293	269
Percent Change (as a percent)	8.90%
Consumer Health | Women's Health
Sales by segment of business
Sales to customers	$ 222	232
Percent Change (as a percent)	(4.30%)
Consumer Health | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 3	4
Percent Change (as a percent)	(25.80%)
Consumer Health | Women's Health | International
Sales by segment of business
Sales to customers	$ 219	228
Percent Change (as a percent)	(3.90%)
Consumer Health | Wound Care/Other
Sales by segment of business
Sales to customers	$ 177	171
Percent Change (as a percent)	3.30%
Consumer Health | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 115	119
Percent Change (as a percent)	(3.00%)
Consumer Health | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 61	52
Percent Change (as a percent)	17.60%
PHARMACEUTICAL
Sales by segment of business
Sales to customers	$ 12,199	11,134
Percent Change (as a percent)	9.60%
PHARMACEUTICAL | U.S.
Sales by segment of business
Sales to customers	$ 6,446	6,061
Percent Change (as a percent)	6.40%
PHARMACEUTICAL | International
Sales by segment of business
Sales to customers	$ 5,753	5,073
Percent Change (as a percent)	13.40%
PHARMACEUTICAL | Immunology
Sales by segment of business
Sales to customers	$ 3,914	3,638
Percent Change (as a percent)	7.60%
PHARMACEUTICAL | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,413	2,410
Percent Change (as a percent)	0.10%
PHARMACEUTICAL | Immunology | International
Sales by segment of business
Sales to customers	$ 1,501	1,228
Percent Change (as a percent)	22.30%
PHARMACEUTICAL | Immunology | REMICADE®
Sales by segment of business
Sales to customers	$ 777	990
Percent Change (as a percent)	(21.50%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S.
Sales by segment of business
Sales to customers	$ 489	625
Percent Change (as a percent)	(21.70%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports
Sales by segment of business
Sales to customers	$ 57	110
Percent Change (as a percent)	(48.40%)
PHARMACEUTICAL | Immunology | REMICADE® | International
Sales by segment of business
Sales to customers	$ 232	256
Percent Change (as a percent)	(9.40%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA®
Sales by segment of business
Sales to customers	$ 562	529
Percent Change (as a percent)	6.20%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S.
Sales by segment of business
Sales to customers	$ 255	272
Percent Change (as a percent)	(5.90%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International
Sales by segment of business
Sales to customers	$ 307	258
Percent Change (as a percent)	18.90%
PHARMACEUTICAL | Immunology | STELARA®
Sales by segment of business
Sales to customers	$ 2,148	1,819
Percent Change (as a percent)	18.10%
PHARMACEUTICAL | Immunology | STELARA® | U.S.
Sales by segment of business
Sales to customers	$ 1,331	1,217
Percent Change (as a percent)	9.40%
PHARMACEUTICAL | Immunology | STELARA® | International
Sales by segment of business
Sales to customers	$ 817	603
Percent Change (as a percent)	35.60%
PHARMACEUTICAL | Immunology | TREMFYA®
Sales by segment of business
Sales to customers	$ 418	296
Percent Change (as a percent)	41.00%
PHARMACEUTICAL | Immunology | TREMFYA® | U.S.
Sales by segment of business
Sales to customers	$ 274	187
Percent Change (as a percent)	46.30%
PHARMACEUTICAL | Immunology | TREMFYA® | International
Sales by segment of business
Sales to customers	$ 143	109
Percent Change (as a percent)	32.00%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 8	3
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	7	0
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	$ 2	3
Percent Change (as a percent)	(38.40%)
PHARMACEUTICAL | Infectious Diseases
Sales by segment of business
Sales to customers	$ 1,007	920
Percent Change (as a percent)	9.50%
PHARMACEUTICAL | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 512	436
Percent Change (as a percent)	17.40%
PHARMACEUTICAL | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 494	483
Percent Change (as a percent)	2.30%
PHARMACEUTICAL | Infectious Diseases | COVID-19
Sales by segment of business
Sales to customers	$ 100	0
PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S.
Sales by segment of business
Sales to customers	100	0
PHARMACEUTICAL | Infectious Diseases | COVID-19 | International
Sales by segment of business
Sales to customers	0	0
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine
Sales by segment of business
Sales to customers	$ 243	224
Percent Change (as a percent)	8.60%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 10	12
Percent Change (as a percent)	(12.30%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International
Sales by segment of business
Sales to customers	$ 233	212
Percent Change (as a percent)	9.80%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
Sales by segment of business
Sales to customers	$ 546	579
Percent Change (as a percent)	(5.80%)
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S.
Sales by segment of business
Sales to customers	$ 380	396
Percent Change (as a percent)	(3.80%)
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International
Sales by segment of business
Sales to customers	$ 166	184
Percent Change (as a percent)	(9.90%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES
Sales by segment of business
Sales to customers	$ 117	116
Percent Change (as a percent)	0.60%
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.
Sales by segment of business
Sales to customers	$ 21	29
Percent Change (as a percent)	(27.00%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International
Sales by segment of business
Sales to customers	$ 96	87
Percent Change (as a percent)	9.70%
PHARMACEUTICAL | Neuroscience
Sales by segment of business
Sales to customers	$ 1,721	1,658
Percent Change (as a percent)	3.80%
PHARMACEUTICAL | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 771	748
Percent Change (as a percent)	3.20%
PHARMACEUTICAL | Neuroscience | International
Sales by segment of business
Sales to customers	$ 949	910
Percent Change (as a percent)	4.30%
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate
Sales by segment of business
Sales to customers	$ 171	171
Percent Change (as a percent)	0.20%
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 47	52
Percent Change (as a percent)	(9.60%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International
Sales by segment of business
Sales to customers	$ 123	118
Percent Change (as a percent)	4.50%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
Sales by segment of business
Sales to customers	$ 965	883
Percent Change (as a percent)	9.40%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S.
Sales by segment of business
Sales to customers	$ 589	544
Percent Change (as a percent)	8.30%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International
Sales by segment of business
Sales to customers	$ 376	339
Percent Change (as a percent)	11.00%
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA®
Sales by segment of business
Sales to customers	$ 157	170
Percent Change (as a percent)	(7.90%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S.
Sales by segment of business
Sales to customers	$ 67	76
Percent Change (as a percent)	(11.80%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International
Sales by segment of business
Sales to customers	$ 89	94
Percent Change (as a percent)	(4.80%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 428	435
Percent Change (as a percent)	(1.50%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 67	75
Percent Change (as a percent)	(9.80%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 361	360
Percent Change (as a percent)	0.20%
PHARMACEUTICAL | Oncology
Sales by segment of business
Sales to customers	$ 3,570	3,013
Percent Change (as a percent)	18.50%
PHARMACEUTICAL | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,377	1,175
Percent Change (as a percent)	17.20%
PHARMACEUTICAL | Oncology | International
Sales by segment of business
Sales to customers	$ 2,193	1,839
Percent Change (as a percent)	19.30%
PHARMACEUTICAL | Oncology | DARZALEX®
Sales by segment of business
Sales to customers	$ 1,365	937
Percent Change (as a percent)	45.60%
PHARMACEUTICAL | Oncology | DARZALEX® | U.S.
Sales by segment of business
Sales to customers	$ 691	463
Percent Change (as a percent)	49.20%
PHARMACEUTICAL | Oncology | DARZALEX® | International
Sales by segment of business
Sales to customers	$ 674	474
Percent Change (as a percent)	42.20%
PHARMACEUTICAL | Oncology | ERLEADA
Sales by segment of business
Sales to customers	$ 261	143
Percent Change (as a percent)	82.80%
PHARMACEUTICAL | Oncology | ERLEADA | U.S.
Sales by segment of business
Sales to customers	$ 171	119
Percent Change (as a percent)	44.00%
PHARMACEUTICAL | Oncology | ERLEADA | International
Sales by segment of business
Sales to customers	$ 90	24
PHARMACEUTICAL | Oncology | IMBRUVICA®
Sales by segment of business
Sales to customers	$ 1,125	1,031
Percent Change (as a percent)	9.00%
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S.
Sales by segment of business
Sales to customers	$ 444	432
Percent Change (as a percent)	2.80%
PHARMACEUTICAL | Oncology | IMBRUVICA® | International
Sales by segment of business
Sales to customers	$ 680	599
Percent Change (as a percent)	13.50%
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate
Sales by segment of business
Sales to customers	$ 638	690
Percent Change (as a percent)	(7.60%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 50	139
Percent Change (as a percent)	(64.20%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 588	552
Percent Change (as a percent)	6.60%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1)
Sales by segment of business
Sales to customers	$ 182	212
Percent Change (as a percent)	(14.20%)
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | U.S.
Sales by segment of business
Sales to customers	$ 21	22
Percent Change (as a percent)	(5.10%)
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | International
Sales by segment of business
Sales to customers	$ 161	190
Percent Change (as a percent)	(15.30%)
PHARMACEUTICAL | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 861	745
Percent Change (as a percent)	15.50%
PHARMACEUTICAL | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 573	486
Percent Change (as a percent)	18.00%
PHARMACEUTICAL | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 288	260
Percent Change (as a percent)	10.80%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT®
Sales by segment of business
Sales to customers	$ 450	389
Percent Change (as a percent)	15.60%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S.
Sales by segment of business
Sales to customers	$ 272	229
Percent Change (as a percent)	18.50%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International
Sales by segment of business
Sales to customers	$ 179	160
Percent Change (as a percent)	11.50%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI®
Sales by segment of business
Sales to customers	$ 305	250
Percent Change (as a percent)	22.00%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S.
Sales by segment of business
Sales to customers	$ 259	212
Percent Change (as a percent)	21.90%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International
Sales by segment of business
Sales to customers	$ 46	38
Percent Change (as a percent)	23.00%
PHARMACEUTICAL | Pulmonary Hypertension | Other
Sales by segment of business
Sales to customers	$ 105	106
Percent Change (as a percent)	(0.60%)
PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S.
Sales by segment of business
Sales to customers	$ 42	44
Percent Change (as a percent)	(3.50%)
PHARMACEUTICAL | Pulmonary Hypertension | Other | International
Sales by segment of business
Sales to customers	$ 63	62
Percent Change (as a percent)	1.40%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 1,127	1,160
Percent Change (as a percent)	(2.80%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 799	806
Percent Change (as a percent)	(0.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 328	354
Percent Change (as a percent)	(7.20%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO®
Sales by segment of business
Sales to customers	$ 589	527
Percent Change (as a percent)	11.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S.
Sales by segment of business
Sales to customers	$ 589	527
Percent Change (as a percent)	11.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International
Sales by segment of business
Sales to customers	$ 0	0
Percent Change (as a percent)	0.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET®
Sales by segment of business
Sales to customers	$ 150	175
Percent Change (as a percent)	(14.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S.
Sales by segment of business
Sales to customers	$ 87	117
Percent Change (as a percent)	(26.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International
Sales by segment of business
Sales to customers	$ 63	58
Percent Change (as a percent)	9.20%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX®
Sales by segment of business
Sales to customers	$ 127	155
Percent Change (as a percent)	(18.20%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S.
Sales by segment of business
Sales to customers	$ 62	76
Percent Change (as a percent)	(18.30%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International
Sales by segment of business
Sales to customers	$ 64	79
Percent Change (as a percent)	(18.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other
Sales by segment of business
Sales to customers	$ 261	302
Percent Change (as a percent)	(13.60%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S.
Sales by segment of business
Sales to customers	$ 60	85
Percent Change (as a percent)	(28.80%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International
Sales by segment of business
Sales to customers	$ 201	217
Percent Change (as a percent)	(7.70%)
MEDICAL DEVICES
Sales by segment of business
Sales to customers	$ 6,579	5,932
Percent Change (as a percent)	10.90%
MEDICAL DEVICES | U.S.
Sales by segment of business
Sales to customers	$ 3,054	2,898
Percent Change (as a percent)	5.40%
MEDICAL DEVICES | International
Sales by segment of business
Sales to customers	$ 3,525	3,034
Percent Change (as a percent)	16.20%
MEDICAL DEVICES | Interventional Solutions
Sales by segment of business
Sales to customers	$ 949	727
Percent Change (as a percent)	30.40%
MEDICAL DEVICES | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 434	365
Percent Change (as a percent)	19.00%
MEDICAL DEVICES | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 514	362
Percent Change (as a percent)	42.00%
MEDICAL DEVICES | Orthopaedics
Sales by segment of business
Sales to customers	$ 2,113	2,038
Percent Change (as a percent)	3.70%
MEDICAL DEVICES | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 1,249	1,250
Percent Change (as a percent)	(0.10%)
MEDICAL DEVICES | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 864	788
Percent Change (as a percent)	9.70%
MEDICAL DEVICES | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 357	337
Percent Change (as a percent)	5.80%
MEDICAL DEVICES | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 210	206
Percent Change (as a percent)	2.40%
MEDICAL DEVICES | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 146	132
Percent Change (as a percent)	11.20%
MEDICAL DEVICES | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 317	343
Percent Change (as a percent)	(7.60%)
MEDICAL DEVICES | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 185	214
Percent Change (as a percent)	(13.50%)
MEDICAL DEVICES | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 132	130
Percent Change (as a percent)	2.00%
MEDICAL DEVICES | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 733	654
Percent Change (as a percent)	12.10%
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 450	407
Percent Change (as a percent)	10.70%
MEDICAL DEVICES | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 282	247
Percent Change (as a percent)	14.40%
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 706	703
Percent Change (as a percent)	0.40%
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 403	423
Percent Change (as a percent)	(4.80%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International
Sales by segment of business
Sales to customers	$ 303	280
Percent Change (as a percent)	8.40%
MEDICAL DEVICES | Surgery
Sales by segment of business
Sales to customers	$ 2,372	2,100
Percent Change (as a percent)	12.90%
MEDICAL DEVICES | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 898	844
Percent Change (as a percent)	6.50%
MEDICAL DEVICES | Surgery | International
Sales by segment of business
Sales to customers	$ 1,474	1,257
Percent Change (as a percent)	17.30%
MEDICAL DEVICES | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 1,118	948
Percent Change (as a percent)	18.00%
MEDICAL DEVICES | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 405	381
Percent Change (as a percent)	6.50%
MEDICAL DEVICES | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 713	567
Percent Change (as a percent)	25.70%
MEDICAL DEVICES | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 1,254	1,153
Percent Change (as a percent)	8.80%
MEDICAL DEVICES | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 493	463
Percent Change (as a percent)	6.50%
MEDICAL DEVICES | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 761	690
Percent Change (as a percent)	10.30%
MEDICAL DEVICES | Vision
Sales by segment of business
Sales to customers	$ 1,145	1,067
Percent Change (as a percent)	7.30%
MEDICAL DEVICES | Vision | U.S.
Sales by segment of business
Sales to customers	$ 472	439
Percent Change (as a percent)	7.40%
MEDICAL DEVICES | Vision | International
Sales by segment of business
Sales to customers	$ 673	628
Percent Change (as a percent)	7.30%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 857	814
Percent Change (as a percent)	5.30%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 371	346
Percent Change (as a percent)	7.20%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 486	467
Percent Change (as a percent)	4.00%
MEDICAL DEVICES | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 288	253
Percent Change (as a percent)	13.70%
MEDICAL DEVICES | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 101	93
Percent Change (as a percent)	8.20%
MEDICAL DEVICES | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 187	$ 160
Percent Change (as a percent)	17.00%

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Segment Reporting Information [Line Items]
Percentage Change in Operating Income Loss	14.10%
Earnings before provision for taxes on income	$ 7,429	$ 6,509
Amount prepaid and due to manufacturers	1,000
Reversal of contingent consideration	0	983
Restructuring charges	53	58
PHARMACEUTICAL
Segment Reporting Information [Line Items]
Litigation expense		100
Medical Devices
Segment Reporting Information [Line Items]
Restructuring charges	100	100
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 7,640	6,629
Percentage Change in Operating Income Loss	15.30%
Operating Segments | Consumer Health
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 788	770
Percentage Change in Operating Income Loss	2.30%
Amortization	$ 100	100
Operating Segments | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 5,223	3,834
Percentage Change in Operating Income Loss	36.20%
Amortization	$ 900	800
Gain (Loss) on Disposition of Assets	600
Unrealized Gain (Loss) on Securities		(300)
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 1,629	2,025
Percentage Change in Operating Income Loss	(19.60%)
Amortization	$ 300	200
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 211	120
Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration		983
Other Income | Auris Health | Medical Devices
Segment Reporting Information [Line Items]
Reversal of contingent consideration		$ 1,000

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Sales by geographic area
Sales	$ 22,321	$ 20,691
Percentage Change In Sales By Geographic Area	7.90%
United States
Sales by geographic area
Sales	$ 11,111	10,699
Percentage Change In Sales By Geographic Area	3.90%
Europe
Sales by geographic area
Sales	$ 5,414	4,827
Percentage Change In Sales By Geographic Area	12.10%
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,424	1,502
Percentage Change In Sales By Geographic Area	(5.10%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 4,372	$ 3,663
Percentage Change In Sales By Geographic Area	19.40%

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020	Jan. 03, 2021
Business Acquisition [Line Items]
Goodwill (Note 3)	$ 35,688		$ 36,393
bermekimab
Business Acquisition [Line Items]
Business acquisition cost		$ 800
Intangible assets		800
Verb Surgical Inc.
Business Acquisition [Line Items]
Intangible assets		400
Goodwill (Note 3)		200
Other assets		200
Liabilities assumed		300
Fair value of previously held equity investment		$ 400
Evra and Doxil
Business Acquisition [Line Items]
Gain (Loss) on Disposition of Assets	$ 600

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	Jan. 20, 2020USD ($)	Jun. 28, 2020USD ($)	Jan. 31, 2020USD ($)	Oct. 31, 2019USD ($)	Jul. 31, 2018USD ($)	Apr. 04, 2021USD ($)claimantpatient	Oct. 31, 2020USD ($)
ASR
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						300
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						7,000
Pelvic Meshes
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						12,200
Risperdal
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						9,200
XARELTO®
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						10,200
Talc
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						28,900
Invokana
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						300
Physiomesh
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						4,400
Opioid
Legal Proceeding (Textuals)
Product liability contingency, number of claimants						3,200
Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $	$ 344		$ 6.8	$ 8,000
Pending Litigation
Legal Proceeding (Textuals)
Loss contingency, estimate of possible loss | $				$ 4,000			$ 5,000
Loss contingency, estimate of additional possible loss | $							$ 1,000
DePuy ASR U.S. | settled Litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient						10,000
Baby Powder | Judicial Ruling | Damages from Product Defects
Legal Proceeding (Textuals)
Litigation contingency | $		$ 2,100			$ 4,700	$ 2,500
Oklahoma Attorney General vs. Johnson & Johnson and JPI | settled Litigation
Legal Proceeding (Textuals)
Damages awarded | $						$ 465

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 53	$ 58
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	104
Restructuring charges recorded to date	1,400
Supply Chain | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	53
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	27
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	24
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Cost savings expected	600
Restructuring estimated cost	1,900
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Cost savings expected	800
Restructuring estimated cost	2,300
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 100	$ 100
Medical Devices | Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Period for activity	4 years
Medical Devices | Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Period for activity	5 years

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Mar. 29, 2020
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 53	$ 58
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning	144
Restructuring charges	104
Payments for Restructuring	(96)
Restructuring Reserve, Settled without Cash	(14)
Reserve balance ending	$ 138
Period of cash outlays for severance expected to be paid out	18 months
Medical Devices | Employee Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning	$ 135
Restructuring charges	0
Payments for Restructuring	(5)
Restructuring Reserve, Settled without Cash	0
Reserve balance ending	130
Medical Devices | Asset Write-off
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0
Restructuring charges	14
Payments for Restructuring	0
Restructuring Reserve, Settled without Cash	(14)
Reserve balance ending	0
Medical Devices | Other Restructuring
Restructuring Reserve [Roll Forward]
Reserve balance beginning	9
Restructuring charges	90
Payments for Restructuring	(91)
Restructuring Reserve, Settled without Cash
Reserve balance ending	$ 8